US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Inspire Corporate Bond ETF

23.63

+0.03030.13%

Volume:46.21K

Turnover:1.09M

Market Cap:493.83M

PE:- -

High:23.65

Open:23.65

Low:23.59

Close:23.60

52wk High:24.78

52wk Low:22.94

Shares:20.90M

Float Shares:20.90M

Volume Ratio:0.76

T/O Rate:0.22%

Dividend:1.01

Dividend Rate:4.26%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

How to Put Out Wildfires Fueled by World War II Ammo? Try Driverless Tanks.

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Press Release: Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Press Release: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update

Inspire International ETF (nyse: Wwjd) Surpasses $500 Million in Assets Under Management

THOMSON REUTERS

How a Hotter Planet is Changing the Business of Sports

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

Press Release: Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Mabwell Gets FDA Clearance for Inflammatory Bowel Disease Drug

MT Newswires Live

Veeco Announces $250 Million+ in Equipment Orders for Manufacturing Indium Phosphide Lasers

Press Release: Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/IBD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":23.6299,"timestamp":1787769744215,"preClose":23.5996,"halted":0,"volume":46206,"delay":0,"changeRate":0.0012839200664418228,"floatShares":20898591,"shares":20898591,"eps":0,"marketStatus":"Trading","change":0.0303,"latestTime":"08-26 14:46:56 EDT","open":23.645,"high":23.645,"low":23.585,"amount":1091072.720556,"amplitude":0.002542,"askPrice":23.63,"askSize":200,"bidPrice":23.53,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787774400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":23.5996,"sharesOutstanding":19800000,"nav":23.63,"aum":496157595.44,"dividendRate":0.04262,"bidAskSpread":0.001783,"postHourTrading":{"tag":"盘后","latestPrice":23.69,"preClose":23.69,"latestTime":"19:30 EDT","volume":15,"amount":355.35,"timestamp":1787700602385,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.764191},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","floatShares":20898591,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.764191,"shares":20898591,"dividePrice":1.0071,"high":23.645,"amplitude":0.002542,"preClose":23.5996,"low":23.585,"week52Low":22.9401,"pbRate":"--","week52High":24.78,"institutionHeld":0,"latestPrice":23.6299,"committee":-0.333333,"eps":0,"divideRate":0.04262,"volume":46206,"delay":0,"ttmEps":0,"open":23.645,"prevYearClose":24.2,"prevWeekClose":23.64,"prevMonthClose":23.6,"prevQuarterClose":23.77,"fiveDayClose":23.67,"twentyDayClose":23.53,"sixtyDayClose":23.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBD\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"IBD","amount":0.0904,"announcedDate":"2026-08-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-26","defaultRemindTime":1787751000000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-26","currency":"USD","dateTimestamp":1787716800000,"payDate":"2026-08-31"},{"date":"2026-07-24","symbol":"IBD","amount":0.0762,"announcedDate":"2026-07-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-24","defaultRemindTime":1784899800000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-29","payableDate":"2026-07-24","currency":"USD","dateTimestamp":1784865600000,"payDate":"2026-07-29"},{"date":"2026-06-26","symbol":"IBD","amount":0.0959,"announcedDate":"2026-06-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-26","defaultRemindTime":1782480600000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-01","payableDate":"2026-06-26","currency":"USD","dateTimestamp":1782446400000,"payDate":"2026-07-01"},{"date":"2026-05-22","symbol":"IBD","amount":0.0776,"announcedDate":"2026-05-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-22","defaultRemindTime":1779456600000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-27","payableDate":"2026-05-22","currency":"USD","dateTimestamp":1779422400000,"payDate":"2026-05-27"},{"date":"2026-04-24","symbol":"IBD","amount":0.0788,"announcedDate":"2026-04-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-24","defaultRemindTime":1777037400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-29","payableDate":"2026-04-24","currency":"USD","dateTimestamp":1777003200000,"payDate":"2026-04-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBD\",market:\"US\",,,undefined,":[{"executeDate":"2017-08-16","recordDate":"2017-08-18","paymentDate":"2017-08-23","value":0.0405,"currency":"USD"},{"executeDate":"2017-09-18","recordDate":"2017-09-19","paymentDate":"2017-09-25","value":0.0292,"currency":"USD"},{"executeDate":"2017-10-16","recordDate":"2017-10-17","paymentDate":"2017-10-23","value":0.0347,"currency":"USD"},{"executeDate":"2017-11-16","recordDate":"2017-11-17","paymentDate":"2017-11-28","value":0.0389,"currency":"USD"},{"executeDate":"2018-01-29","recordDate":"2018-01-30","paymentDate":"2018-02-05","value":0.0269,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660874612","title":"How to Put Out Wildfires Fueled by World War II Ammo? Try Driverless Tanks.","url":"https://stock-news.laohu8.com/highlight/detail?id=2660874612","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660874612?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:30","pubTimestamp":1787232600,"startTime":"0","endTime":"0","summary":"Ed BallardConsuming a few hundred acres, the fire in the Hürtgen Forest, western Germany, was a mere barbecue compared with the conflagrations that have recently threatened Mediterranean tourist spots","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660178421","title":"Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2660178421","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660178421?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:26","pubTimestamp":1787142360,"startTime":"0","endTime":"0","summary":"Proposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected byyear-end RA is a $24 billion m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/19/3347616/0/en/chemomab-therapeutics-announces-second-quarter-2026-financial-results-and-provides-corporate-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","PSC","RA","BK4539","MTRS","IBD","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658952508","title":"Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952508","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658952508?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:20","pubTimestamp":1786393200,"startTime":"0","endTime":"0","summary":"Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patien","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3342259/0/en/palisade-bio-reports-second-quarter-2026-financial-results-and-highlights-continued-advancement-of-pali-2108-into-phase-2-development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","LU2237443465.HKD","CD","LU1169590202.USD","LU2237443978.SGD","IE00BKVL7J92.USD","LU0149725797.USD","LU2746668461.USD","IE00B1BXHZ80.USD","LU0267386448.USD","BK4007","LU2237443895.HKD","BK4116","BK4127","LU1363072403.SGD","IND","CMC","PD","LU2237443382.USD","LU2237443622.USD","BK4023","LU0882574139.USD","IBD","BK4006","BK4139","PALI","IE00BFXG1179.USD","HYLG","LU1169589451.USD","IE00BHPRN162.USD","IDNA","LU0971096721.USD","LU2237443549.SGD","MEDX","LU0170899867.USD","GDOC","IE00BZ1G4Q59.USD","LU2746668974.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658982936","title":"Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658982936","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658982936?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:03","pubTimestamp":1786359780,"startTime":"0","endTime":"0","summary":"EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341704/0/en/oruka-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","BK4007","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657256955","title":"Press Release: Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657256955","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657256955?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:02","pubTimestamp":1785873720,"startTime":"0","endTime":"0","summary":"Announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial (\"SKYLINE\"), demonstrating best-in-class efficacy potential and a safety profile consistent wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LFSC","BK4539","IBD","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655877001","title":"Press Release: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655877001","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655877001?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:30","pubTimestamp":1785414600,"startTime":"0","endTime":"0","summary":"-- Completed Type A meeting with the FDA on bitopertin and aligned that the. Phase 3 APOLLO study, if successful, can serve as the basis for CRL. -- Presented positive clinical data updates from the RALLY-MF Phase 2 trial. of selcodebart  in anemia of myelofibrosis and the HELIOS. -- Completed enrollment for RESTORE-PV Phase 2 study of DISC-3405 in. polycythemia vera  with initial data expected in Q3 2026 and. progressing Phase 1b study of DISC-3405 in sickle cell disease  with. -- Strong financial position ending Q2 with approximately $718 million in. cash, cash equivalents, and marketable securities, providing runway into. in erythropoietic protoporphyria  and aligned that the Phase 3. APOLLO study, if successful, can serve as the basis for CRL response and. -- Presented updated data from the HELIOS open-label extension trial of. bitopertin in EPP at the European Hematology Association  Annual. Meeting, demonstrating sustained reductions in protoporphyrin IX ,significant improvement ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRON","BK4113","IBD","EPP","LU0053671581.USD","MF","BK4139","BK4563","DISC","BK4539","BK4582","BK4526","SCD","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653238203","title":"Inspire International ETF (nyse: Wwjd) Surpasses $500 Million in Assets Under Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2653238203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653238203?lang=en_us&edition=fundamental","pubTime":"2026-07-21 22:01","pubTimestamp":1784642474,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nTUA5WTVL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ISMD","WWJD","FDLS","IBD","BIBL","GLRY","PTL","RISN","BLES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651476594","title":"How a Hotter Planet is Changing the Business of Sports","url":"https://stock-news.laohu8.com/highlight/detail?id=2651476594","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651476594?lang=en_us&edition=fundamental","pubTime":"2026-07-16 21:30","pubTimestamp":1784208600,"startTime":"0","endTime":"0","summary":"Ed BallardThe World Cup's hydration breaks have gone down about as well as eggnog on a baking-hot day.Fans have booed the three-minute pauses, which are mandatory even in air-conditioned stadiums. Cri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VWAPY","IBD","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641489805","title":"Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses","url":"https://stock-news.laohu8.com/highlight/detail?id=2641489805","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641489805?lang=en_us&edition=fundamental","pubTime":"2026-06-08 19:00","pubTimestamp":1780916400,"startTime":"0","endTime":"0","summary":"KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models KT-579 Phase 1 healthy volunteer trial","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/08/3307932/0/en/Kymera-Therapeutics-Presents-New-Preclinical-Lupus-Data-for-KT-579-First-in-Class-Oral-IRF5-Degrader-at-EULAR-and-FOCIS-Congresses.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004220.SGD","LU0541501648.USD","RA","LU0541502299.USD","BK4139","IBD","KT","KYMR","BK4115"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635363712","title":"Press Release: Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635363712","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635363712?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760000,"startTime":"0","endTime":"0","summary":"--New Clinical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC Patients with Co-Existing IBD--. --Company Continues to Advance Multiple Partnering Options for Nebokitug--. TEL AVIV, Israel, May 14, 2026  -- Chemomab Therapeutics Ltd. , , a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2026, and provided a corporate update.-- On May 30, 2026, Chemomab will present data from three abstracts at EASL. -- In one EASL 2026 study1, Olink-generated analyses of circulating. proteins in patient samples from the SPRING trial were used to. generate an AI/machine learning model to identify patients who. showed a combined improvement in all three key fibrosis-related. measures: ELF sc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4139","LENZ","R","BK6053","CD","PSC","BK4023","DM0.SI","BK4007","BK4116","CMMB","IBD","BK4539","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634477456","title":"Mabwell Gets FDA Clearance for Inflammatory Bowel Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2634477456","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634477456?lang=en_us&edition=fundamental","pubTime":"2026-05-11 14:20","pubTimestamp":1778480432,"startTime":"0","endTime":"0","summary":"Mabwell  Bioscience's  clinical trial application for 9MW521, a novel injection targeting Inflammatory Bowel Disease , was formally cleared by the US Food and Drug Administration, according to a May 8 Hong Kong bourse filing.Shares of the pharmaceutical firm were up nearly 4% in Monday afternoon trading.The drug will be tested as a treatment for inflammatory bowel disease.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK1161","BK4588","LABU","688062","BK4585","02493","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633925059","title":"Veeco Announces $250 Million+ in Equipment Orders for Manufacturing Indium Phosphide Lasers","url":"https://stock-news.laohu8.com/highlight/detail?id=2633925059","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633925059?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:03","pubTimestamp":1778011380,"startTime":"0","endTime":"0","summary":"High-volume orders from multiple customers for its Spector, Lumina and Wet Processing Systems to drive strong growth. PLAINVIEW, N.Y., May  05, 2026 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (NASDAQ:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3288217/0/en/Veeco-Announces-250-Million-in-Equipment-Orders-for-Manufacturing-Indium-Phosphide-Lasers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4147","VECO","IBD","IE00B19Z4B17.USD","IE00B7SZL793.SGD","IE0031619046.USD","IE00B66KJ199.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633948138","title":"Press Release: Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633948138","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633948138?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:30","pubTimestamp":1777984200,"startTime":"0","endTime":"0","summary":"-- Completed enrollment of the Phase 3 APOLLO study of bitopertin in. erythropoietic protoporphyria ; topline data expected in Q4 2026. -- Updated data from Phase 2 study of DISC-0974 in patients with anemia of. myelofibrosis  to be shared at the American Society of Clinical. -- Progressing ongoing Phase 2 study of DISC-3405 in polycythemia vera . and Phase 1b study of DISC-3405 in sickle cell disease , with data. cash, cash equivalents, and marketable securities, providing runway into. adults and adolescents with EPP, with topline data expected Q4 2026;anemia of myelofibrosis  to be shared in an oral presentation at ASCO. -- Progressing Phase 2 study in patients with inflammatory bowel disease","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0053671581.USD","BK4582","EPP","IRON","SCD","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632305519","title":"Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2632305519","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632305519?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:00","pubTimestamp":1777892400,"startTime":"0","endTime":"0","summary":"Data highlight both SER-603’s rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3286554/0/en/Seres-Therapeutics-Presents-Preclinical-Data-at-Digestive-Disease-Week-DDW-2026-Supporting-SER-603-a-Next-Generation-Cultivated-Live-Biotherapeutic-Candidate-for-Inflammatory-Bowel.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCRB","IBD","BK4139","SER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631636287","title":"Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2631636287","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631636287?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:00","pubTimestamp":1777546800,"startTime":"0","endTime":"0","summary":"KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to K","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284687/0/en/Kymera-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","LU0072461881.USD","SID","BK4132","BK4201","AD","ATS","BP","IBD","BK4161","BK4006","KYMR","LU1829250122.USD","BK4096","LU0006061336.USD","BK4585","LU0162691827.USD","BK4139","BK4588","LU1162221912.USD","EASI","PN","LU0320765646.SGD","BPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629837806","title":"InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2629837806","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629837806?lang=en_us&edition=fundamental","pubTime":"2026-04-23 21:20","pubTimestamp":1776950400,"startTime":"0","endTime":"0","summary":"BEIJING, April  23, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced its results and business highlights for the first quarter of 2026 as of 31 March 2026. Over the ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/23/3280053/0/en/InnoCare-Releases-2026-Q1-Results-Strong-Revenue-Growth-and-Sustained-Profitability.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1732800096.USD","AD","LU0795875086.SGD","LU0314104364.USD","BK4504","LU0882574139.USD","LU1720051017.SGD","BK4127","LU1244550577.SGD","LU2028103732.USD","LU0795875169.SGD","BK4534","LU1989772923.USD","IE00BKVL7J92.USD","BK4132","LU1732799900.SGD","LU2023251221.USD","BK4199","LU2271345857.HKD","SLE","LU1074936037.SGD","LU2347655156.SGD","BK4588","LU1162221912.USD","LU1244550221.USD","LU0971096721.USD","LU0234570918.USD","BK4581","LU0006306889.USD","LU0106831901.USD","LU0158827781.USD","IBD","ITP","LU2357305700.SGD","BK4585","LU2089284900.SGD","LU0320765646.SGD","LU0158827948.USD","LU1244550494.USD","BK4516","LU2133065610.SGD","LU2089283258.USD","BK4077","LU0557290698.USD","LU0912757837.SGD","LU0106261372.USD","LU2111349929.HKD","LU0528227936.USD","LU0225283273.USD","LU1791710400.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628174260","title":"Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2628174260","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628174260?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:00","pubTimestamp":1776682800,"startTime":"0","endTime":"0","summary":"Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration Additional presentations underscore the role of live b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/20/3276845/0/en/Seres-Therapeutics-Showcases-SER-155-Data-and-Live-Biotherapeutic-Insights-at-ESCMID-Global-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","AMR","BK4585","MCRB","BK4139","SER","BK4006","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628559249","title":"Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2628559249","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628559249?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:15","pubTimestamp":1776370500,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., April  16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and ant","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/16/3275826/0/en/Spyre-Therapeutics-Inc-Announces-Closing-of-Public-Offering-and-Full-Exercise-of-the-Underwriters-Option-to-Purchase-Additional-Shares-for-Gross-Proceeds-of-463-5-Million.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","IBD","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627714114","title":"Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2627714114","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627714114?lang=en_us&edition=fundamental","pubTime":"2026-04-15 10:38","pubTimestamp":1776220680,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., April  14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/15/3274098/0/en/Spyre-Therapeutics-Announces-Pricing-of-Upsized-403-0-Million-Public-Offering-of-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","BK4007","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627465756","title":"Spyre Therapeutics Announces Proposed Public Offering of its Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2627465756","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627465756?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:46","pubTimestamp":1776113160,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., April  13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/13/3272916/0/en/Spyre-Therapeutics-Announces-Proposed-Public-Offering-of-its-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4007","IBD","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}]}}